International Journal of Molecular Medical Science, 2024, Vol.14, No.4, 216-226 http://medscipublisher.com/index.php/ijmms 223 al., 2019). However, the challenge remains in identifying the causal mechanisms behind these associations, as GWAS results often highlight genomic regions without direct links to biological functions (Ormel et al., 2019). Future research should focus on integrating data from various omic pillars, such as genomics, epigenomics, proteomics, and metabolomics, to create a comprehensive understanding of the biological pathways involved in depression and its treatment (Amare et al., 2017). Additionally, advances in DNA methylation studies have shown potential in identifying biomarkers for treatment response in major depressive disorder (MDD) (Alladi et al., 2018). These epigenetic modifications can provide insights into gene-environment interactions that influence both the pathophysiology and treatment response of depression. As genomic technologies continue to evolve, the development of more sophisticated tools for data integration and analysis will be crucial in advancing personalized medicine in psychiatry (Amare et al., 2017; Alladi et al., 2018). 6.2 Expanding personalized treatment Personalized treatment for depression aims to tailor therapeutic interventions based on an individual's genetic makeup, clinical characteristics, and other biomarkers. Pharmacogenomic studies have already identified several genetic variants that influence the efficacy of antidepressants and mood stabilizers, such as selective serotonin reuptake inhibitors (SSRIs) and lithium (Amare et al., 2017). These findings have led to the development of genotyping tests that can guide medication selection, improving treatment outcomes by identifying responders and non-responders, and minimizing adverse drug events (Miller and O'Callaghan, 2013). Despite these advancements, the clinical utility of genetic biomarkers for personalized treatment remains limited. Future research should focus on improving the design of pharmacogenomic studies by incorporating larger cohorts, more comprehensive genetic analyses, and the integration of clinical-demographic predictors (Fabbri et al., 2018). Additionally, the development of multivariable diagnostic or prognostic algorithms that combine genomic information with other predictors, such as neuroimaging and clinical characteristics, could enhance the accuracy of treatment predictions (Amare et al., 2017). The use of deep learning and other advanced computational techniques also holds promise for predicting antidepressant response and remission. By analyzing genetic and clinical factors, these models can identify complex relationships between biomarkers and treatment outcomes, potentially leading to more effective personalized treatment strategies (Lin et al., 2018). 6.3 Interdisciplinary research The future of personalized treatment for depression lies in interdisciplinary research that combines expertise from various fields, including genomics, psychiatry, bioinformatics, and clinical practice. Collaborative efforts are essential to address the complexities of depression and its treatment, as well as to develop innovative approaches for integrating diverse data types. One area of interdisciplinary research that shows promise is the integration of pharmacogenomics with other omic data, such as proteomics and metabolomics, to identify novel biomarkers and therapeutic targets (Holsboer, 2008; Amare et al., 2017; Chen et al., 2024). This systems genomics approach aims to understand the biological pathways and networks underlying drug response, ultimately leading to more precise and effective treatments. Another important aspect of interdisciplinary research is the collaboration between basic and clinical scientists to translate genomic findings into clinical practice. This includes the development of diagnostic tests, therapeutic interventions, and predictive algorithms that can be used by clinicians to guide treatment decisions (Miller and O'Callaghan, 2013; Amare et al., 2017). Additionally, the involvement of bioinformaticians and data scientists is crucial for developing advanced computational tools and models that can handle the complexity of genomic and clinical data (Lin et al., 2018). Interdisciplinary research should also focus on addressing the ethical, legal, and social implications of personalized medicine. This includes ensuring patient privacy and data security, as well as addressing potential
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==